Segall Bryant & Hamill LLC Trims Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Segall Bryant & Hamill LLC trimmed its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 3.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 112,617 shares of the company’s stock after selling 4,599 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in TransMedics Group were worth $17,681,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. International Assets Investment Management LLC purchased a new position in TransMedics Group during the second quarter worth about $47,000. USA Financial Formulas acquired a new stake in shares of TransMedics Group in the 3rd quarter valued at $55,000. J.Safra Asset Management Corp increased its holdings in TransMedics Group by 649.2% in the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after buying an additional 383 shares during the last quarter. Signaturefd LLC increased its holdings in shares of TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after acquiring an additional 93 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in TransMedics Group by 187.0% during the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after purchasing an additional 316 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. TD Cowen reduced their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research note on Monday. Baird R W raised TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Oppenheimer dropped their price target on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. Piper Sandler lowered their price target on TransMedics Group from $180.00 to $110.00 and set an “overweight” rating on the stock in a research report on Wednesday. Finally, Needham & Company LLC dropped their price target on TransMedics Group from $208.00 to $109.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $131.80.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the transaction, the director now directly owns 732 shares in the company, valued at $61,158.60. This represents a 90.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This trade represents a 12.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 36,958 shares of company stock valued at $5,230,528 in the last quarter. Company insiders own 7.00% of the company’s stock.

TransMedics Group Trading Down 6.9 %

Shares of NASDAQ:TMDX opened at $77.20 on Thursday. TransMedics Group, Inc. has a 1 year low of $66.76 and a 1 year high of $177.37. The business’s 50 day simple moving average is $123.41 and its 200 day simple moving average is $138.93. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company has a market capitalization of $2.59 billion, a P/E ratio of 82.13 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. During the same period in the prior year, the firm earned ($0.12) earnings per share. TransMedics Group’s revenue was up 63.7% compared to the same quarter last year. On average, research analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.